• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新冠病毒感染和ChAdOx1 nCoV-19（AZD1222）疫苗接种后发生的伏格特-小柳-原田综合征

Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine.

作者信息

Saraceno Janaína Jamile Ferreira, Souza Guilherme Macedo, Dos Santos Finamor Luciana Peixoto, Nascimento Heloisa Moraes, Belfort Rubens

机构信息

Department of Ophthalmology, Hospital Sao Rafael, Salvador, Brazil.

Department of Ophthalmology and Visual Science, Federal University of Sao Paulo, Sao Paulo, Brazil.

出版信息

Int J Retina Vitreous. 2021 Aug 30;7(1):49. doi: 10.1186/s40942-021-00319-3.

DOI:10.1186/s40942-021-00319-3
PMID:34462013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8404022/
Abstract

The challenge of COVID-19 has rapidly changed medical management worldwide. The relatively small time from pandemic to vaccines regulatory approval triggered a race toward vaccines development. However, important questions regarding SARS-CoV-2 vaccines remain. A case of complete Vogt-Koyanagi-Harada (VKH) Syndrome that occurred 4 days following SARS-CoV-2 vaccination and another patient that developed VKH 14 days post COVID-19 clinical onset are presented. A causal relationship between COVID-19 and uveitis may exist.

摘要

新冠疫情的挑战迅速改变了全球的医疗管理方式。从疫情大流行到疫苗获得监管批准的时间相对较短，引发了一场疫苗研发竞赛。然而，关于新冠病毒疫苗仍存在重要问题。本文报告了1例在接种新冠病毒疫苗后4天出现的完全性葡萄膜炎-小柳原田综合征（VKH综合征）病例，以及另1例在新冠临床发病14天后出现VKH综合征的患者。新冠病毒感染与葡萄膜炎之间可能存在因果关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/1f312c24e237/40942_2021_319_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/039403c317a7/40942_2021_319_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/96c809fb44a5/40942_2021_319_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/4ae87bc88dbe/40942_2021_319_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/cead2499fa5f/40942_2021_319_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/ff709c2bd67e/40942_2021_319_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/3a872015a0a6/40942_2021_319_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/dda749eaa526/40942_2021_319_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/eb209c89c561/40942_2021_319_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/1f312c24e237/40942_2021_319_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/039403c317a7/40942_2021_319_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/96c809fb44a5/40942_2021_319_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/4ae87bc88dbe/40942_2021_319_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/cead2499fa5f/40942_2021_319_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/ff709c2bd67e/40942_2021_319_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/3a872015a0a6/40942_2021_319_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/dda749eaa526/40942_2021_319_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/eb209c89c561/40942_2021_319_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b40c/8404265/1f312c24e237/40942_2021_319_Fig9_HTML.jpg

相似文献

1
Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine.新冠病毒感染和ChAdOx1 nCoV-19（AZD1222）疫苗接种后发生的伏格特-小柳-原田综合征
Int J Retina Vitreous. 2021 Aug 30;7(1):49. doi: 10.1186/s40942-021-00319-3.
2
Possible Association between Vogt-Koyanagi-Harada Disease and Coronavirus Disease Vaccine: A Report of Four Cases.可能与 Vogt-Koyanagi-Harada 病和冠状病毒病疫苗有关：四例报告。
Ocul Immunol Inflamm. 2023 Aug;31(6):1134-1140. doi: 10.1080/09273948.2022.2093756. Epub 2022 Aug 1.
3
Bilateral Panuveitis Mimicking Vogt-Koyanagi-Harada Disease following the First Dose of ChAdOx1 nCoV-19 Vaccine.接种 ChAdOx1 nCoV-19 疫苗第一针后双侧全葡萄膜炎，类似 Vogt-Koyanagi-Harada 病。
Ocul Immunol Inflamm. 2022 Jul;30(5):1218-1221. doi: 10.1080/09273948.2022.2026410. Epub 2022 Feb 3.
4
Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination.接种 ChAdOx1 nCoV-19 和 mRNA-1273 后发生 Vogt-Koyanagi-Harada 病。
J Fr Ophtalmol. 2023 Mar;46(3):207-210. doi: 10.1016/j.jfo.2022.09.017. Epub 2023 Feb 10.
5
Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine.与 COVID-19 疫苗相关的 Vogt-Koyanagi-Harada 病恶化。
Cells. 2022 Mar 16;11(6):1012. doi: 10.3390/cells11061012.
6
Vogt-Koyanagi-Harada Disease and COVID.伏格特-小柳-原田病与新冠病毒
J Clin Med. 2023 Sep 27;12(19):6242. doi: 10.3390/jcm12196242.
7
Probable Vogt-Koyanagi-Harada Disease after COVID-19 Vaccination: Case Report and Literature Review.新冠疫苗接种后疑似小柳原田病：病例报告与文献综述
Vaccines (Basel). 2022 May 16;10(5):783. doi: 10.3390/vaccines10050783.
8
Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222).急性横贯性脊髓炎（ATM）：43例新冠病毒相关急性横贯性脊髓炎患者及3例接种ChAdOx1 nCoV-19疫苗（AZD1222）后发生的急性横贯性脊髓炎严重不良事件的临床回顾
Front Immunol. 2021 Apr 26;12:653786. doi: 10.3389/fimmu.2021.653786. eCollection 2021.
9
Harada-like syndrome post-Covishield vaccination: A rare adverse effect.科维希尔德疫苗接种后出现原田综合征样综合征：一种罕见的不良反应。
Indian J Ophthalmol. 2022 Jan;70(1):321-323. doi: 10.4103/ijo.IJO_2589_21.
10
Uveitis and Other Ocular Complications Following COVID-19 Vaccination.新冠疫苗接种后的葡萄膜炎及其他眼部并发症
J Clin Med. 2021 Dec 19;10(24):5960. doi: 10.3390/jcm10245960.

引用本文的文献

1
Effect of the COVID-19 pandemic on Vogt-Koyanagi-Harada disease.COVID-19 大流行对 Vogt-Koyanagi-Harada 病的影响。
Sci Rep. 2024 Jun 8;14(1):13211. doi: 10.1038/s41598-024-63957-1.
2
Vogt-Koyanagi-Harada disease after SARS-CoV-2 infection: Case report and literature review.新型冠状病毒感染后发生的伏格特-小柳-原田病：病例报告及文献综述
Immun Inflamm Dis. 2024 Apr;12(4):e1250. doi: 10.1002/iid3.1250.
3
Questionnaire survey of risk factors for recurrence of ocular inflammation in patients with uveitis after SARS-CoV-2 infection.

本文引用的文献

1
Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.接受 BNT162b2 疫苗接种后结直肠癌患者出现细胞因子释放综合征。
Nat Med. 2021 Aug;27(8):1362-1366. doi: 10.1038/s41591-021-01387-6. Epub 2021 May 26.
2
Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1.首例接种黑猩猩腺病毒载体 COVID-19 疫苗（ChAdOx1）后出现的吉兰-巴雷综合征。
BMJ Case Rep. 2021 Apr 22;14(4):e242956. doi: 10.1136/bcr-2021-242956.
3
COVID-19 and autoimmune diseases.
新型冠状病毒感染后葡萄膜炎患者眼部炎症复发的危险因素的问卷调查研究。
Front Cell Infect Microbiol. 2024 Jan 30;13:1291991. doi: 10.3389/fcimb.2023.1291991. eCollection 2023.
4
Vogt-Koyanagi-Harada Disease and COVID.伏格特-小柳-原田病与新冠病毒
J Clin Med. 2023 Sep 27;12(19):6242. doi: 10.3390/jcm12196242.
5
Case Report: Spectrum of interesting ocular manifestations following COVID-19 vaccination: a case series of real-world presentations.病例报告：COVID-19疫苗接种后有趣的眼部表现谱：一系列真实病例展示
Front Cell Infect Microbiol. 2023 Sep 15;13:1243055. doi: 10.3389/fcimb.2023.1243055. eCollection 2023.
6
Ocular manifestations following COVID-19 vaccination.新型冠状病毒肺炎疫苗接种后的眼部表现。
J Ophthalmic Inflamm Infect. 2023 Sep 23;13(1):44. doi: 10.1186/s12348-023-00358-x.
7
Correction.更正。
Hum Vaccin Immunother. 2023 Aug;19(2):2259160. doi: 10.1080/21645515.2023.2259160. Epub 2023 Sep 21.
8
Challenges in posterior uveitis-tips and tricks for the retina specialist.后葡萄膜炎的挑战——视网膜专科医生的小贴士和技巧
J Ophthalmic Inflamm Infect. 2023 Aug 17;13(1):35. doi: 10.1186/s12348-023-00342-5.
9
A COVID-19 perspective of Vogt-Koyanagi-Harada disease.Vogt-Koyanagi-Harada 病的 COVID-19 视角。
Indian J Ophthalmol. 2023 Jun;71(6):2587-2591. doi: 10.4103/IJO.IJO_172_23.
10
Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease.COVID-19 疫苗相关 Vogt-Koyanagi-Harada 病的临床特征、诊断和治疗。
Hum Vaccin Immunother. 2023 Aug 1;19(2):2220630. doi: 10.1080/21645515.2023.2220630. Epub 2023 Jun 6.
新型冠状病毒肺炎与自身免疫性疾病。
Curr Opin Rheumatol. 2021 Mar 1;33(2):155-162. doi: 10.1097/BOR.0000000000000776.
4
Oxford-AstraZeneca COVID-19 vaccine efficacy.牛津大学-阿斯利康新冠疫苗的效力
Lancet. 2021 Jan 9;397(10269):72-74. doi: 10.1016/S0140-6736(20)32623-4. Epub 2020 Dec 8.
5
Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4 T Cells in COVID-19.COVID-19 中 SARS-CoV-2 反应性调节性和细胞毒性 CD4 T 细胞的失衡。
Cell. 2020 Nov 25;183(5):1340-1353.e16. doi: 10.1016/j.cell.2020.10.001. Epub 2020 Oct 5.
6
Vogt-Koyanagi-Harada disease presenting secondary to a post-infectious autoimmune response.继发于感染后自身免疫反应的Vogt-小柳-原田病。
Am J Ophthalmol Case Rep. 2020 Jun 22;19:100793. doi: 10.1016/j.ajoc.2020.100793. eCollection 2020 Sep.
7
Vogt-Koyanagi-Harada Disease following Yellow Fever Vaccination.黄热病疫苗接种后 Vogt-Koyanagi-Harada 病。
Ocul Immunol Inflamm. 2021 Jan 2;29(1):124-127. doi: 10.1080/09273948.2019.1661498. Epub 2019 Oct 11.
8
Vogt-Koyanagi-Harada Disease Associated with Influenza A Virus Infection.与甲型流感病毒感染相关的葡萄膜炎-小柳原田病
Intern Med. 2018 Jun 1;57(11):1661-1665. doi: 10.2169/internalmedicine.9819-17. Epub 2018 Jan 11.
9
Induction of Vogt-Koyanagi-Harada Disease by Interferon-Alpha and Ribavirin Treatment in Patients with Hepatitis C: A Case Report and Review of the Literature.干扰素-α和利巴韦林治疗丙型肝炎诱导 Vogt-Koyanagi-Harada 病：病例报告及文献复习。
Ocul Immunol Inflamm. 2019;27(2):229-234. doi: 10.1080/09273948.2017.1373827. Epub 2017 Oct 12.
10
Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma.沃格特－小柳－原田样综合征并发派姆单抗治疗转移性黑色素瘤
J Immunother. 2017 Feb/Mar;40(2):77-82. doi: 10.1097/CJI.0000000000000154.